Doxorubicin Market Report Explored in Latest Research 2025
Doxorubicin is the generic drug name for anti-cancer chemotherapy drug Adriamycin and Rubex. Doxorubicin is an anthracycline antibiotic and belongs to the group of anti-cancer medication known as antineoplastic and is made from the natural product produced by bacterium Streptomyces peucetius var. caesius.Request Brochure-
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26138
It is used for the treatment of different types of cancer including breast, stomach, ovary, bone, testicles, bladder, lung, soft tissue, osteogenic sarcoma, Wilms’ tumor, and Hodgkin’s and non-Hodgkin’s lymphomas. It is also used less commonly in the treatment of squamous cell carcinomas of the head and neck. Vagina and cervix, refractory multiple myeloma, and neuroblastoma. Doxorubicin inhibits and or slows the rate of proliferation of cancerous cells by intercalating between the base pairs in the DNA helix, thereby preventing DNA replication and inhibiting protein synthesis.
This medication is available in injection solution and lyophilized powder form and is administered intravenously either through peripheral inserted central line catheters (PICC) or central venous catheters (CVC). The dosage of this medication depends on the type and severity of cancer, and type of other medication used during treatments and is most commonly scheduled at 21 days of every dosage.
The global doxorubicin market is anticipated to expand at a higher growth rate owing to increasing prevalence of cancer patients worldwide. According to the WHO, cancer is the leading cause of death globally, accounting 8.8 million deaths in 2015. The number of new cases is expected to increase by 70% in the next two decades. The global market for this drug is also expected to be driven by increasing use in the treatment of HIV-associated Kaposi sarcoma. HIV-associated Kaposi sarcoma has markedly increased in countries in Africa and the West in the last two decades.
View Report-
https://www.transparencymarketresearch.com/doxorubicin-market.html
On the other hand, doxorubicin medication can cause life threatening conditions such as heart failure during therapy or sometimes after months or years after treatment. Additionally, it can cause side effects such as nausea, vomiting, diarrhea, loss of appetite, and reddish urine after one to two days of treatment. These side effects, specifically cardio toxicity, imposes a limitation on the use of doxorubicin and creates an opportunity for development of lipid based (liposome) formulations with improved therapeutic index of conventional doxorubicin.
The global doxorubicin drug market has been segmented based on drug formulation, type of cancer, distribution channel, and region. In terms of drug formulation, the market has been segmented into lyophilized powder and doxorubicin injection. It is administered through the vein either peripherally or through central venous catheter. Based on type of cancer, the market has been segmented into lung cancer, Hodgkin’s and non-Hodgkin’s cancer, breast cancer, prostate cancer, ovary cancer, stomach cancer, leukemia, and others. Lung and breast cancer are expected to be major segments of the global doxorubicin market. This medication is available in hospital pharmacy, retail pharmacy, and online pharmacy. Of these distribution channels, hospital pharmacy is projected to be the key segment during the forecast period.
In terms of region, the global doxorubicin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is anticipated to dominate the global doxorubicin market owing to highest number of cancer patients and favorable medical reimbursement policies. North America is the second leading market for doxorubicin. Asia Pacific is projected to be the fastest growing market during the forecast period driven by increasing rate of diagnosis of cancer patients and improving health care accessibility and infrastructure.
Request For Discount-
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26138
Key players operating in the global doxorubicin market are Pfizer, Inc., Johnson & Johnson, Accord Healthcare, Novartis AG, Thymoorgan Pharmazie GmbH, Sun Pharmaceutical Industries Ltd., Allergan, Inc., Meiji Seika Pharma Co., Merrimack Pharmaceuticals, Inc., and Dr. Reddy’s Laboratories Ltd., among others.
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website:www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Doxorubicin Market Report Explored in Latest Research 2025 here
News-ID: 1093537 • Views: …
More Releases from Transparency Market Research
RF Chip Inductor Market Size to Reach over USD 1.8 billion by 2031 - Transparenc …
RF Chip Inductor Market are essential components in various electronic devices, providing inductance and functioning as filters, oscillators, and transformers. They play a crucial role in ensuring the efficiency and performance of RF circuits. With the rapid advancement in telecommunications, consumer electronics, and automotive industries, the demand for RF chip inductors has seen a significant rise. These components are integral in applications such as smartphones, IoT devices, and automotive electronics,…
Solid Tires Market Expected to Witness Impressive Growth at a 8.1% CAGR by 2031
The latest research study released by Transparency Market Research on "Solid Tires Market Forecast to 2023-2031 ″ research provides accurate economic, global, and country-level predictions and analyses.
Solid Tires market is estimated to attain a valuation of US$ 760.0 Mn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 8.1% during…
Automotive Cyber security Market Sales Estimated to Hit USD 10.5 Billion by 2031 …
The latest research study released by Transparency Market Research on "𝐀𝐮𝐭𝐨𝐦𝐨𝐭𝐢𝐯𝐞 𝐂𝐲𝐛𝐞𝐫 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 𝟐𝟎𝟐𝟑-𝟐𝟎𝟑𝟏 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Automotive Cyber security industry, as…
Ready-mix Concrete Market to Witness Exponential Growth with a CAGR of 6.1% from …
The latest research study released by Transparency Market Research on "𝐑𝐞𝐚𝐝𝐲-𝐦𝐢𝐱 𝐂𝐨𝐧𝐜𝐫𝐞𝐭𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 𝟐𝟎𝟐𝟑-𝟐𝟎𝟑𝟏 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Ready-mix Concrete industry, as well as…
More Releases for Doxorubicin
Global Doxorubicin Market Insights, Forecast
Doxorubicin is a kind of antitumor antibiotics, can inhibit the synthesis of RNA and DNA, RNA in the strongest inhibitory effect. Doxorubicin has an effect on a wide variety of tumor, belongs to the cycle non-specific drug, have all sorts of growth cycle of tumor cells to kill.it's given by injection into a vein. The global Doxorubicin market is valued at 910 million US$ in 2018 and will reach 1410…
Doxorubicin Global Industry Report - History, Present and Future 2019
The global market size of Doxorubicin is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023.
There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment.
For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from…
Doxorubicin Market to Reflect Steady Growth Rate by 2024
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the…
Doxorubicin Market to Witness an Outstanding Growth by 2024
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the…
Doxorubicin Market Rugged Expansion Foreseen by 2024
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the…
Global Doxorubicin Market 2017 By Key Manufacturers: Teva
The motive of this strategic research report entitled "Global Doxorubicin Market 2017" is to provide company officials, industry investors, and industry members with consequential insights to enable them make reliable strategic decisions regarding the opportunities in the global Doxorubicin market.
Key Notes On Doxorubicin Market:
"Global Doxorubicin Market 2017 "offers crucial insights into the global Doxorubicin market along with the market size and estimates for the duration 2017 to 2023.
This industry report…